# Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy

> **NCT04787276** · NA · COMPLETED · sponsor: **Bogomolets National Medical University** · enrollment: 42 (actual)

## Conditions studied

- Hepatic Encephalopathy
- Liver Cirrhosis
- End Stage Liver DIsease

## Interventions

- **DIETARY_SUPPLEMENT:** E.coli Nissle 1917
- **DRUG:** Lactulose
- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT04787276
- **Lead sponsor:** Bogomolets National Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-03-15
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787276, "Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04787276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*